Roger J. Butlin

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill et al. · Nature Cancer · 2021 · 251 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +9

AZD7545 is a selective inhibitor of pyruvate dehydrogenase kinase 2

Jenny Morrell, Jon P. Orme, Roger J. Butlin et al. · Biochemical Society Transactions · 2003 · 82 citations

Aldo-keto Reductase, Molecular Biology, Metabolic Remodeling +18

Use of Small-Molecule Crystal Structures To Address Solubility in a Novel Series of G Protein Coupled Receptor 119 Agonists: Optimization of a Lead and in Vivo Evaluation

James S. Scott, Alan M. Birch, Katy J. Brocklehurst et al. · Journal of Medicinal Chemistry · 2012 · 74 citations · Full text

Glycobiology, Chemical Biology, Molecular Recognition +17

A Mild Benzannulation through Directed Cycloaddition Reactions

James D. Kirkham, Roger J. Butlin, Joseph P. A. Harrity · Angewandte Chemie International Edition · 2012 · 61 citations

Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules

Tim Luker, Lilian Alcaraz, Kamaldeep K. Chohan et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 57 citations

Vivo Toxicology Outcomes, Preclinical Drug Evaluation, Pharmacological Study +6